FIG. 35:  How does ADVENT-HF differ from SERVE-HF, and why is it important that this trial should be completed?  Irrespective of the results from SERVE-HF, ADVENT-HF will provide novel data on the effects of treating asymptomatic OSA in patients with heart failure (which is more common than CSA in patients with heart failure), and because, since ADVENT-HF includes CSA and OSA patients, the results should be more generalizable than those of SERVE-HF.